Cover Image
市場調查報告書

與全球主要已開發國家的HIV治療藥市場:開發中產品的功效改善的限制專利失效,醫療費用支出的規定的市場成長率的抑制

HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth

出版商 GBI Research 商品編碼 299449
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
與全球主要已開發國家的HIV治療藥市場:開發中產品的功效改善的限制專利失效,醫療費用支出的規定的市場成長率的抑制 HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth
出版日期: 2014年04月14日 內容資訊: 英文
簡介

全球HIV(人免疫力缺乏病毒)治療藥的市場,隨著主要的治療藥的專利失效,今後一般認為是降低的東西。全球整體的市場規模,2012年143億美元,2019年163億美元,又的最近的年平均成長率(年複合成長率)1.9%被預測。幾個的有前途的開發中產品存在,不過,沒能得到還正式的認證。

本報告提供全球主要已開發國家(美國·英國·法國·德國·義大利·西班牙·日本·加拿大)的HIV治療藥的市場相關分析,疾病概要和目前主要治療方法,現在已上市·臨床實驗中主要的治療藥的概要與臨床實驗的進展,全球及各國的市場趨勢預測(今後7年分),主要的推動及阻礙市場要素,市場最新趨勢(資本交易·共同開發等),今後的市場方向性等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 疾病概要
  • HIV的感染途徑
  • 病因
  • HIV-1亞型的分類
  • 病理
    • HIV-1複製循環
    • CD4表現T細胞的死亡機制
    • 潛伏感染與病毒持續性
  • 症狀
  • 診斷
    • HIV抗體檢定
    • HIV抗體的快速診斷
    • HIV p24抗原檢查
    • 抗原·抗體的免疫分析法
    • 聚合酵素鏈鎖反應檢查
    • HIV的居家檢查用套件
  • 疾病的癌症分期
    • WHO的臨床階段
    • CDC(聯邦防疫中心)的分類系統
    • 免疫學的分類
  • 共生病症和併發症
  • 流行病學
  • 治療選擇
    • 核苷/核苷酸逆轉錄酵素抑制劑
    • 非核苷酸逆轉錄酵素抑制劑
    • 侵入抑制劑
    • 整合酶抑製劑
    • HIV-1蛋白分解酵素抑制劑
    • 藥物動力學的增強劑
  • 治療流程

第3章 已上市產品

  • 治療環境
    • 複數級的組合
    • 核苷酸逆轉錄酵素抑制劑
    • 非核苷酸逆轉錄酵素抑制劑
    • HIV蛋白分解酵素抑制劑
    • Integrase抑制劑
    • 侵入抑制劑
  • 競爭產品的功效和安全性
  • 未滿足需求

第4章 HIV用開發中產品

  • 開發平台的整體情形
  • HIV開發中產品的功能機制
  • 臨床實驗
    • 開發平台的失敗率
    • 臨床實驗的規模
    • 臨床實驗的期間
    • 臨床實驗的摘要與風險分析
  • 開發平台上的有前途的候補藥
    • 572-Trii (dolutegravir + abacavir sulfate + lamivudine) - Shionogi-ViiV Healthcare
    • Atazanavir sulfate + cobicistat - Bristol-Myers Squibb, Gilead
    • Elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide - Gilead
    • Apricitabine - Avexa
    • Remune (IR-103) - Immune Response BioPharma
    • Censavudine - Bristol-Myers Squibb
    • Elvucitabine - Achillion
    • Cenicriviroc - Tobira Therapeutics
  • HIV開發中產品的熱圖與競爭產品矩陣

第5章 市場預測

  • 各地區市場
    • 全球
    • 北美
    • 歐洲主要5個國家
    • 日本
  • 推動及阻礙市場要素

第6章 資本交易及策略性聯盟

  • 主要的共同開發契約(全3件)
  • 主要的授權合約(全6件)

第7章 附錄

圖表一覽

目錄
Product Code: GBIHC328MR

The leading business intelligence provider GBI Research has released its latest research report, entitled,‘HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth’. The report provides insights into the HIV (Human Immunodeficiency Virus) therapeutics market including market forecasts up to 2019. It provides an in-depth analysis of the major marketed products, as well as insights into the HIV therapeutics R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV therapeutics market. The report analyzes the market for HIV therapeutics in eight major markets of the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), Japan and Canada. The report discusses the global pipeline for all the HIV molecules across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. GBI Research found that the HIV therapeutics market in the top seven markets was valued at $14.3 billion in 2012 and is projected to witness growth of 1.9% during the 2012-2019 forecast period to reach $16.3 billion.

Scope

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for HIV.The report covers and includes -

  • A brief introduction to HIV, including the symptoms, pathogenesis, risk factors and diagnosis
  • In-depth analysis of major glucose-lowering drugs for HIV, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
  • Comprehensive review of the pipeline for HIV therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
  • Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action
  • Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy, Spain and Canada
  • Discussion of the drivers and barriers for market growth

Reasons to buy

  • The report will enhance your decision-making capability. It will allow you to -
  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and HIV/AIDS therapeutics market segments poised for strong growth.
  • Create a more tailored country strategy through the understanding of key drivers and barriers of the global HIV/AIDS therapeutics market.
  • Develop key strategic initiatives by understanding the key focus areas and top selling products of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Abstract

Patent Protection Losses Will Hinder HIV Treatment Market Growth Within Seven Years, says GBI Research

Thanks to patent expirations of several key therapies, the Human Immunodeficiency Virus (HIV) treatment market value will increase at a slow pace in the coming years, from $14.3 billion in 2012 to $16.3 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 1.9%, says business intelligence provider GBI Research.

According to the company's latest report*, the first-line antiretroviral therapies Atripla and Truvada will lose patent protection during the forecast period, which will hurt their markets in Europe and Canada.

Angel Wong, Analyst for GBI Research, says: "Despite such patent losses, a number of drugs will enter the HIV market by 2019. Among these new entrants, 572-Trii is expected to perform the strongest commercially and will compete with Atripla following its approval. However, these drugs will not offset the impact of generic erosion."

Currently, the HIV pipeline is strong and displays a high degree of novelty and diversity, according to GBI Research. The pipeline also consists of therapies that address the unmet needs of drug resistance and toxicity. These drugs are Nucleoside Reverse Transcriptase Inhibitor (NRTI) apricitabine, censavudine and elvucitabine, which deal with the issue of NRTI resistance.

Another candidate in the HIV pipeline, which is a new pro-drug of tenofovir, called tenofovir alafenamide, has also demonstrated a more favorable toxicity profile than its predecessor Viread.

Wong says: "Despite the promising outlook, the HIV pipeline has suffered from high attrition rates in recent years, particularly with vaccines. None of these have been approved for the treatment of HIV.

These failures reflect an urgent need for a more thorough understanding of immune response against HIV and more streamlined clinical trial designs," the analyst concludes.

HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth

This report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for HIV. Countries covered in this report include the US, France, Germany, Italy, Spain, the UK, Japan and Canada.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Route of HIV Transmission
  • 2.3. Etiology
  • 2.4. Classification of HIV-1 Subtypes
  • 2.5. Pathophysiology
    • 2.5.1. HIV-1 Replication Cycle
    • 2.5.2. Mechanism of CD4 T-Cell Death
    • 2.5.3. Latent Infection and Viral Persistence
  • 2.6. Symptoms
  • 2.7. Diagnosis
    • 2.7.1. HIV Antibody Assay
    • 2.7.2. Rapid HIV Antibody Test
    • 2.7.3. Western Blot
    • 2.7.4. HIV p24 Antigen Test
    • 2.7.5. Antigen-Antibody Immunoassay
    • 2.7.6. Polymerase Chain Reaction Test
    • 2.7.7. HIV Home-Testing Kit
  • 2.8. Disease Staging
    • 2.8.1. WHO Clinical Staging
    • 2.8.2. Centers for Disease Control and Prevention Classification System
    • 2.8.3. Immunological Classification
  • 2.9. Co-morbidities and Complications
  • 2.10. Epidemiology
  • 2.11. Treatment Options
    • 2.11.1. Nucleoside/Nucleotide Reverse Transcriptase Inhibitor
    • 2.11.2. Non-Nucleoside Reverse Transcriptase Inhibitor
    • 2.11.3. Entry Inhibitor
    • 2.11.4. Integrase Inhibitor
    • 2.11.5. HIV-1 Protease Inhibitor
    • 2.11.6. Pharmacokinetic Enhancer
  • 2.12. Treatment Algorithm

3. Marketed Products

  • 3.1. Therapeutic Landscape
    • 3.1.1. Multi-class Combinations
    • 3.1.2. Nucleotide Reverse Transcriptase Inhibitors
    • 3.1.3. Non-Nucleoside Reverse Transcriptase Inhibitor
    • 3.1.4. HIV Protease Inhibitor
    • 3.1.5. Integrase Inhibitor
    • 3.1.6. Entry Inhibitor
  • 3.2. Comparative Efficacy and Safety
    • 3.2.1. Multi-class Combination
    • 3.2.2. Nucleotide Reverse Transcriptase Inhibitor
    • 3.2.3. Non-Nucleotide Reverse Transcriptase Inhibitor
    • 3.2.4. HIV Protease Inhibitor
    • 3.2.5. Integrase Inhibitor
    • 3.2.6. Entry Inhibitor
  • 3.3. Unmet Need

4. Pipeline for HIV

  • 4.1. Overall Pipeline
  • 4.2. Mechanism of Action in HIV Pipeline
  • 4.3. Clinical Trials
    • 4.3.1. Failure Rate of Developmental Pipeline
    • 4.3.2. Clinical Trial Sizes
    • 4.3.3. Clinical Trial Duration
    • 4.3.4. Summary of Clinical Trial and Risk Analysis
  • 4.4. Promising Candidates in Pipeline
    • 4.4.1. 572-Trii (dolutegravir + abacavir sulfate + lamivudine) - Shionogi-ViiV Healthcare
    • 4.4.2. Atazanavir sulfate + cobicistat - Bristol-Myers Squibb, Gilead
    • 4.4.3. Elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide - Gilead
    • 4.4.4. Apricitabine - Avexa
    • 4.4.5. Remune (IR-103) - Immune Response BioPharma
    • 4.4.6. Censavudine - Bristol-Myers Squibb
    • 4.4.7. Elvucitabine - Achillion
    • 4.4.8. Cenicriviroc - Tobira Therapeutics
  • 4.5. Heat Map and Competitor Matrix for HIV Pipeline Products

5. Market Forecast to 2019

  • 5.1. Geographical Markets
    • 5.1.1. Global Market
    • 5.1.2. North America
    • 5.1.3. Top Five Countries in Europe
    • 5.1.4. Japan
  • 5.2. Drivers and Barriers
    • 5.2.1. Drivers
    • 5.2.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Major Co-development Deals
    • 6.1.1. DFH Pharma Enters Agreement with Hetero Drugs
    • 6.1.2. GlaxoSmithKline Enters Agreement with Concert Pharmaceuticals
    • 6.1.3. GenVec Enters Agreement with SAIC-Frederick
  • 6.2. Major Licensing Deals
    • 6.2.1. Merck Enters Agreement with Chimerix
    • 6.2.2. Bristol-Myers Squibb Enters Agreement with Gilead
    • 6.2.3. Japan Tobacco Enters Agreement with Gilead
    • 6.2.4. Gilead Enters Agreement with Tibotec
    • 6.2.5. Benitec Enters Agreement with Calimmune
    • 6.2.6. Bristol-Myers Squibb Enters Agreement with Oncolys BioPharma

7. Appendix

  • 7.1. All Pipeline Products, by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. Phase I
    • 7.1.4. Phase II
    • 7.1.5. Phase III and Pre-registration
  • 7.2. Tabular Forecast Data
    • 7.2.1. Global
    • 7.2.2. US
    • 7.2.3. Canada
    • 7.2.4. UK
    • 7.2.5. France
    • 7.2.6. Germany
    • 7.2.7. Italy
    • 7.2.8. Spain
    • 7.2.9. Japan
  • 7.3. Sources
  • 7.4. Market Definition
  • 7.5. Abbreviations
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
  • 7.7. Therapeutic Landscape
  • 7.8. Epidemiology-Based Forecasting
  • 7.9. Market Size by Geography
  • 7.10. Geographical Landscape
  • 7.11. Pipeline Analysis
  • 7.12. Competitive Landscape
    • 7.12.1. Expert Panel Validation
  • 7.13. Contact Us
  • 7.14. Disclaimer

List of Tables

  • Table 1: HIV Therapeutics Market, Subtypes of HIV-1 and Geographical Patterns, 2013
  • Table 2: HIV Therapeutics Market, World Health Organization's Clinical Staging of HIV/AIDS for Adults and Adolescents with Confirmed HIV Infection, 2014
  • Table 3: HIV Therapeutics Market, US Centers for Disease Control and Prevention's Classification System for Adults and Adolescents with HIV, 1993-2014
  • Table 4: HIV Therapeutics Market, World Health Organization's Immunological Classification for Adults and Children with Established HIV, 2014
  • Table 5: HIV Therapeutics Market, Global, Expected Patent Expirations in the HIV Market, 2013-2019
  • Table 6: All Pipeline Products, by Phase, Discovery
  • Table 7: All Pipeline Products, by Phase, Preclinical
  • Table 8: All Pipeline Products, by Phase, Phase I
  • Table 9: All Pipeline Products, by Phase, Phase II
  • Table 10: All Pipeline Products, by Phase, Phase III and Pre-registration
  • Table 11: HIV Theraputic Market, Global, Market Forecast, 2012-2019
  • Table 12: HIV Therapeutic Market, US, Market Forecast, 2012-2019
  • Table 13: HIV Therapeutic Market, Canada, Market Forecast, 2012-2019
  • Table 14: HIV Therapeutic Market, UK, Market Forecast, 2012-2019
  • Table 15: HIV Therapeutic Market, France, Market Forecast, 2012-2019
  • Table 16: HIV Therapeutic Market, Germany, Market Forecast, 2012-2019
  • Table 17: HIV Therapeutic Market, Italy, Market Forecast, 2012-2019
  • Table 18: HIV Therapeutic Market, Spain, Market Forecast, 2012-2019
  • Table 19: HIV Therapeutic Market, Japan, Market Forecast, 2012-2019

List of Figures

  • Figure 1: HIV Therapeutics Market, Treatment Algorithm for HIV-infected Adults and Adolescents under World Health Organization Guidelines, 2013
  • Figure 2: HIV Therapeutics Market, Treatment Algorithm for Infants and Children with HIV under World Health Organization Guidelines, 2013
  • Figure 3: HIV Therapeutics Market, Global, Annual Sales of Key Marketed Products ($bn), 2013
  • Figure 4: HIV Therapeutics Market, Global, Annual Sales of Atripla ($bn), 2006-2013
  • Figure 5: HIV Therapeutics Market, Global, Annual Sales of Complera ($m), 2011-2013
  • Figure 6: HIV Therapeutics Market, Global, Annual Sales of Truvada ($bn), 2004-2013
  • Figure 7: HIV Therapeutics Market, Global, Annual Sales of Epzicom ($m), 2004-2013
  • Figure 8: HIV Therapeutics Market, Global, Annual Sales of Viread ($m), 2001-2013
  • Figure 9: HIV Therapeutics Market, Global, Annual Sales of Combivir ($m), 2000-2013
  • Figure 10: HIV Therapeutics Market, Global, Annual Sales of Trizivir ($m), 2000-2013
  • Figure 11: HIV Therapeutics Market, Global, Annual Sales of Epivir ($m), 1996-2013
  • Figure 12: HIV Therapeutics Market, Global, Annual Sales of Sustiva ($m), 2001-2013
  • Figure 13: HIV Therapeutics Market, Global, Annual Sales of Intelence ($m), 2010-2013
  • Figure 14: HIV Therapeutics Market, Global, Annual Sales of Reyataz ($m), 2003-2013
  • Figure 15: HIV Therapeutics Market, Global, Annual Sales of Prezista ($m), 2006-2013
  • Figure 16: HIV Therapeutics Market, Global, Annual Sales of Kaletra ($bn), 2009-2012
  • Figure 17: HIV Therapeutics Market, Global, Annual Sales of Norvir ($m), 2010-2012
  • Figure 18: HIV Therapeutics Market, Global, Annual Sales of Isentress ($m), 2007-2013
  • Figure 19: HIV Therapeutics Market, Global, Annual Sales of Selzentry ($m), 2010-2013
  • Figure 20: HIV Therapeutics Market, Global, Heat Map of Marketed Products, 2013
  • Figure 21: HIV Therapeutics Market, Global, Overall Pipeline, 2014
  • Figure 22: HIV Therapeutics Market, Global, Breakdown of Biologics and Vaccine, 2014
  • Figure 23: HIV Therapeutics Market, Global, Mechanism of Action in the Pipeline, 2014
  • Figure 24: HIV Therapeutics Market, Global, Clinical Trial Failure Rate by Molecule Type, 2006-2013
  • Figure 25: HIV Therapeutics Market, Global, Clinical Trial Failure Rate by Mechanism of Action, 2006-2013
  • Figure 26: HIV Therapeutics Market, Global, Clinical Trial Failure Reasons, 2006-2013
  • Figure 27: HIV Therapeutics Market, Global, Mean Recruitment Size of Clinical Trial by Molecule Type (Participants), 2006-2013
  • Figure 28: HIV Therapeutics Market, Global, Mean Recruitment Size of Clinical Trial by Mechanism of Action (Participants), 2006-2013
  • Figure 29: HIV Therapeutics Market, Global, Mean Duration of Clinical Trial by Molecule Type (Months), 2006-2013*
  • Figure 30: HIV Therapeutics Market, Global, Mean Duration of clinical Trial by Mechanism of Action (Months), 2006-2013
  • Figure 31: HIV Therapeutics Market, Global, Failure Rate, Duration and Recruitment Size by Mechanism of Action, 2006-2013
  • Figure 32: HIV Therapeutics Market, Global, Sales Forecast for 572-Trii ($bn), 2014-2019
  • Figure 33: HIV Therapeutics Market, Global, Sales Forecast for Atazanavir Sulfate + Cobicistat ($m), 2014-2019
  • Figure 34: HIV Therapeutics Market, Global, Sales Forecast for Elvitegravir + Cobicistat + Emtricitabine + Tenofovir Alafenamide ($m), 2015-2019
  • Figure 35: HIV Therapeutics Market, Global, Sales Forecast for Apricitabine ($m), 2016-2019
  • Figure 36: HIV Therapeutics Market, Global, Sales Forecast for Censavudine ($m), 2016-2019
  • Figure 37: HIV Therapeutics Market, Global, Sales Forecast for Elvucitabine ($m), 2016-2019
  • Figure 38: HIV Therapeutics Market, Global, Sales Forecast for Cenicriviroc ($m), 2016-2019
  • Figure 39: HIV Therapeutics Market, Global, Heat Map of Pipeline Products, 2013
  • Figure 40: HIV Therapeutics Market, Global, Competitor Matrix, 2013
  • Figure 41: HIV Therapeutics Market, Global, Treatment Patterns and Market Size, 2012-2019
  • Figure 42: HIV Therapeutics Market, North America, Treatment Patterns, 2012-2019
  • Figure 43: HIV Therapeutics Market, North America, Annual Cost of Therapy ($), 2012-2019
  • Figure 44: HIV Therapeutics Market, North America, Market Size, 2012-2019
  • Figure 45: HIV Therapeutics Market, Top Five European Countries, Treatment Patterns ('000), 2012-2019
  • Figure 46: HIV Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2012-2019
  • Figure 47: HIV Therapeutics Market, Top Five European Countries, Market Size ($m), 2012-2019
  • Figure 48: HIV Therapeutics Market, Japan, Treatment Patterns and Annual Cost of Therapy, 2012-2019
  • Figure 49: HIV Therapeutics Market, Japan, Market Size ($m), 2012-2019
  • Figure 50: HIV Therapeutics Market, Global, Co-development Deals, 2006-2014*
  • Figure 51: HIV Therapeutics Market, Global, Co-development Deals, 2006-2014
  • Figure 52: HIV Therapeutics Market, Global, Licensing Deals, 2006-2014*
  • Figure 53: HIV Therapeutics Market, Global, Licensing Deals, 2006-2014
  • Figure 54: HIV Therapeutics Market, Global, Licensing Deals by Mechanism of Action, 2006-2014
  • Figure 55: GBI Research Market Forecasting Model
Back to Top